|
Wednesday, January 3, 2007
Merck Sharp and Dohme Limited has been reinstated to membership
of the Association of the British Pharmaceutical Industry (ABPI)
following the company's suspension on October 2, 2006.
The ABPI Board of Management noted that the importance of complying
with the ABPI Code of Practice had been made clear to all Merck
Sharp and Dohme staff, and an audit report in November referred
to the company's commitment to compliance and its progress in recent
months. The ABPI Board agreed that the momentum generated needed
to be maintained.
The ABPI Board decided that Merck Sharp and Dohme should be reinstated
to membership with effect from January 3, but that there should
be a further audit within six months to ensure progress is being
maintained.
Merck Sharp and Dohme was suspended from membership for a minimum
of three months after it was found to be in breach of the code,
including Clause 2 which deals with activities that bring discredit
on, or reduce confidence in, the pharmaceutical industry.
For further information, please contact:
Richard Ley (office) 020 7747 1410 (mobile) 07715 169727
Ben Hayes (office) 020 7747 1406 (mobile) 07715 169726
|
